Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Details)

v3.25.0.1
Commitments and Contingencies - Additional Information (Details)
12 Months Ended
Sep. 08, 2020
Debtinstrument
Jan. 21, 2020
Debtinstrument
Dec. 31, 2024
USD ($)
UsdRln
Nov. 18, 2015
USD ($)
Royalty-Linked Notes        
Other Commitments [Line Items]        
Debt instrument outstanding portion | UsdRln     0.04  
Debt instrument maturity date     Dec. 31, 2045  
Debt instrument price per unit | $     $ 160  
Debt instrument, aggregate potential payment capped rate     4,000  
Royalty-Linked Notes | Private Placement        
Other Commitments [Line Items]        
Number of debt instruments issued | Debtinstrument   2,579,400    
Royalty-Linked Notes | Rights Offering        
Other Commitments [Line Items]        
Number of debt instruments issued | Debtinstrument 11,000      
Royalty-Linked Notes | 2020 Rights Offering        
Other Commitments [Line Items]        
Number of debt instruments issued | Debtinstrument 11,000      
Pfizer License Agreement | Minimum        
Other Commitments [Line Items]        
Regulatory and sales milestone payments upon achievement of net sales | $       $ 250,000,000
Pfizer License Agreement | Maximum        
Other Commitments [Line Items]        
Regulatory and sales milestone payments upon achievement of net sales | $       $ 1,000,000,000